Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...
Roche’s Evrysdi Receives NMPA Approval for Wider SMA Patient Age Range
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that its blockbuster nervous system drug Evrysdi...
MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its...
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
Gates Foundation Renews Partnership with Beijing and Tsinghua to Boost Infectious Disease Research
The Bill & Melinda Gates Foundation has announced the renewal of its collaboration with the...
Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion
Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has...
Sperogenix Therapeutics and LUCA Healthcare Join Forces to Advance Digital Therapy for Myasthenia Gravis
China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm...
Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors
China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...
NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement
The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...
Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA
China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial...
Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion
Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...
Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation
China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...
Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma
The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication...
Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica...